Key result
Gut microbiota dysbiosis and associated metabolites contribute to inflammation and endothelial dysfunction, facilitating the onset of cardiovascular diseases such as atherosclerosis and heart failure.
Why the study?
Even when traditional risk factors are treated to target, residual cardiovascular disease risk remains, prompting review of the gut microbiota as a potential contributor and therapeutic target.
Design
Systematic review
Authors
Loading...
Gut microbiota may contribute to residual CV risk; leaves open whether dysbiosis-targeted interventions improve outcomes.
Systematic Review
This review highlights the emerging role of gut microbiota dysbiosis in cardiovascular disease pathogenesis and identifies microbiome modulation as a potential therapeutic target.
Escobar et al. (2025) conducted a systematic review in Cardiovascular disease. Gut microbiota dysbiosis was evaluated. Gut microbiota dysbiosis and associated metabolites contribute to inflammation and endothelial dysfunction, facilitating the onset of cardiovascular diseases such as atherosclerosis and heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: